|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM24862489X |
| 003 |
DE-627 |
| 005 |
20231224151816.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2015 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2015.04.006
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0828.xml
|
| 035 |
|
|
|a (DE-627)NLM24862489X
|
| 035 |
|
|
|a (NLM)25934386
|
| 035 |
|
|
|a (PII)S1521-6616(15)00136-9
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Arron, Joseph R
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Stratified medicine in inflammatory disorders
|b From theory to practice
|
| 264 |
|
1 |
|c 2015
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 01.04.2016
|
| 500 |
|
|
|a Date Revised 31.03.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2015 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Chronic inflammatory disorders are complex and characterized by significant heterogeneity in molecular, pathological, and clinical features. This heterogeneity poses challenges for the development of targeted molecular interventions for these disorders, as not all patients with a given clinical diagnosis have disease driven by a single dominant molecular pathway, hence not all patients will benefit equally from a given intervention. Biomarkers related to molecular manifestations of disease are increasingly being applied to enable stratified approaches to drug development. Biomarkers may be used to identify which patients are most likely to benefit from an intervention (predictive), identify patients at increased risk of disease progression (prognostic), and monitor biological responsiveness to an intervention (pharmacodynamic). Here we consider how biomarker-guided stratification of patients may increase benefit from targeted therapies for asthma, rheumatoid arthritis and inflammatory bowel diseases
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Asthma
|
| 650 |
|
4 |
|a Biomarker
|
| 650 |
|
4 |
|a Rheumatoid arthritis
|
| 650 |
|
4 |
|a Ulcerative colitis
|
| 650 |
|
7 |
|a Anti-Inflammatory Agents
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a Adalimumab
|2 NLM
|
| 650 |
|
7 |
|a FYS6T7F842
|2 NLM
|
| 700 |
1 |
|
|a Townsend, Michael J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Keir, Mary E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yaspan, Brian L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chan, Andrew C
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 161(2015), 1 vom: 15. Nov., Seite 11-22
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:161
|g year:2015
|g number:1
|g day:15
|g month:11
|g pages:11-22
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2015.04.006
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 161
|j 2015
|e 1
|b 15
|c 11
|h 11-22
|